a Department of Nephrology , Chinese PLA General Hospital, National Clinical Research Center for Kidney Diseases, State Key Laboratory of Kidney Diseases, Chinese PLA Institute of Nephrology , Beijing , China.
b Department of Nephrology , China-Japan Friendship Hospital , Beijing 100029 , China.
Clin Exp Hypertens. 2018;40(8):784-791. doi: 10.1080/10641963.2018.1433193. Epub 2018 Mar 6.
Hypertension is prevalent in chronic kidney disease (CKD), but the control of hypertension is suboptimal. We reported the prevalence and characteristics of resistant and undertreated hypertension based on a nationwide survey aiming to improve blood pressure (BP) control.
Resistant hypertension (RH) was defined as BP above the target (<140/90 mm Hg) despite the use of 3 antihypertensive drugs or achieving the target BP by using ≥4 antihypertensive drugs. Undertreated hypertension was defined as uncontrolled hypertension (unCH) using ≤2 drugs. We compared the characteristics and antihypertensive treatment among different groups (including RH and unCH using ≤2 drugs). Multivariable logistic regression was used to detect factors associated with unCH using ≤2 drugs and RH.
4,435 nondialysis CKD patients with hypertension were analyzed, and 36.9% of participants achieved controlled hypertension (CH) using ≤3 drugs, 11.1% met the criteria for RH, and 52% had unCH despite the use of ≤ 2 antihypertensive drugs. Participants with unCH using ≤ 2 drugs had low usage of renin-angiotensin system blockers (36.8%) and diuretics (5.5%), which was much lower than participants with CH using ≤3 drugs and RH (P< 0.05). After multivariable adjustment, obesity, advanced CKD stages, urinary protein level of ≥1.5 g/24 h, diabetes, and cardiovascular disease were associated with RH in CKD patients (P< 0.05).
Compared with RH, undertreated hypertension contributes more to the unCH in Chinese CKD patients. It is important to ensure adequate antihypertensive treatment, including choosing antihypertensive drugs, that guidelines recommended.
高血压在慢性肾脏病(CKD)中很常见,但高血压的控制并不理想。我们根据一项旨在改善血压(BP)控制的全国性调查,报告了抗高血压治疗和治疗不足的高血压的流行率和特征。
抗高血压治疗(RH)定义为使用 3 种降压药物后血压仍高于目标值(<140/90 mmHg),或使用≥4 种降压药物后达到目标血压。治疗不足的高血压定义为使用≤2 种药物未能控制血压(unCH)。我们比较了不同组(包括 RH 和使用≤2 种药物的 unCH)的特征和降压治疗。多变量逻辑回归用于检测与使用≤2 种药物的 unCH 和 RH 相关的因素。
分析了 4435 例非透析 CKD 合并高血压患者,36.9%的患者使用≤3 种药物可达到控制的高血压(CH),11.1%符合 RH 标准,52%尽管使用≤2 种降压药物仍有 unCH。使用≤2 种药物的 unCH 患者肾素-血管紧张素系统阻滞剂(36.8%)和利尿剂(5.5%)的使用率较低,远低于使用≤3 种药物和 RH 的 CH 患者(P<0.05)。多变量调整后,肥胖、CKD 晚期、尿蛋白水平≥1.5 g/24 h、糖尿病和心血管疾病与 CKD 患者的 RH 相关(P<0.05)。
与 RH 相比,治疗不足的高血压在中国 CKD 患者的未控制高血压中起更大的作用。确保充足的降压治疗,包括选择指南推荐的降压药物,非常重要。